Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesalazine - Dr Falk Pharma

Next Previous
Drug Profile

Mesalazine - Dr Falk Pharma

Alternative Names: 5-ASA; AJG501; Apriso; Mesalamine 0.375g extended-release capsules (Apriso) - Salix Pharmaceuticals; Mesalamine granules - Salix Pharmaceuticals; Salofalk; Salofalk Granu-Stix

Latest Information Update: 18 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dr Falk Pharma
  • Developer Ajinomoto; Dr Falk Pharma; Salix Pharmaceuticals
  • Class Aminosalicylic acids; Anti-inflammatories; Antineoplastics; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ulcerative colitis
  • Phase II Colorectal cancer; Eosinophilic oesophagitis; Ulcerative proctitis
  • Discontinued Diverticulitis; Microscopic colitis

Most Recent Events

  • 20 Jul 2023 Dr. Falk Pharma completes a phase IIa trial in Eosinophilic oesophagitis in Switzerland (PO, Suspension) (NCT05488405)
  • 10 Aug 2022 Dr. Falk Pharma plans a phase IIa trial in Eosinophilic oesophagitis in Switzerland (PO, Suspension) in September 2022 (NCT05488405)
  • 08 Mar 2022 Discontinued - Phase-III for Microscopic colitis in Germany, Hungary, Sweden, Denmark, Netherlands, Spain, Lithuania, Czech Republic, Belgium (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top